The Sample Biorepository and Analytics Core Facility (Core C) will continue to provide a secure, standardized, and readily accessible source of human and mouse biologic samples that are integral to testing the hypotheses proposed in the three Projects of this AADCRC. Sample information will be maintained in an FDA-compliant digital database that will be accessible by investigators in Core B to identify samples available for molecular informatics analyses. Core C will also provide standardized and cost-effective methodology for extraction of RNA, protein, and lipid mediators, and for histologic processing and analysis of tissue samples. In addition, the Core will provide state of the art liquid chromatography-tandem mass spectrometry analyses with high sensitivity and the ability to identify >20 eicosanoids from a single sample, which will be essential for quantifying specific mediators as well as defining eicosanoid profiles in patient-derived samples in Projects 1 and 3, as well as the mouse studies in Project 2. The Core activities were implemented during the current funding period, with start-up costs being supported by an Administrative Supplement. Thus, all of the necessary organization, personnel, software, and equipment are already in place. Because this Core supports all three Projects as well as Core B, it is central to the integration of the AADCRC as a whole.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI095219-09
Application #
9703848
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2019-07-01
Budget End
2020-06-30
Support Year
9
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Eid, Ryan C; Palumbo, Marina L; Laidlaw, Tanya M et al. (2018) A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract :
Schneider, Thomas R; Johns, Christina B; Palumbo, Marina L et al. (2018) Dietary Fatty Acid Modification for the Treatment of Aspirin-Exacerbated Respiratory Disease: A Prospective Pilot Trial. J Allergy Clin Immunol Pract 6:825-831
Cardet, Juan Carlos; Louisias, Margee; King, Tonya S et al. (2018) Income is an independent risk factor for worse asthma outcomes. J Allergy Clin Immunol 141:754-760.e3
Ordovas-Montanes, Jose; Dwyer, Daniel F; Nyquist, Sarah K et al. (2018) Allergic inflammatory memory in human respiratory epithelial progenitor cells. Nature 560:649-654
Tuttle, Katherine L; Buchheit, Kathleen M; Laidlaw, Tanya M et al. (2018) A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol Pract 6:1045-1047
Pan, Dingxin; Buchheit, Kathleen M; Samuchiwal, Sachin K et al. (2018) COX-1 mediates IL-33-induced extracellular signal-regulated kinase activation in mast cells: Implications for aspirin sensitivity. J Allergy Clin Immunol :
Liu, Tao; Barrett, Nora A; Kanaoka, Yoshihide et al. (2018) Type 2 Cysteinyl Leukotriene Receptors Drive IL-33-Dependent Type 2 Immunopathology and Aspirin Sensitivity. J Immunol 200:915-927
Putman, Rachel K; Gudmundsson, Gunnar; Araki, Tetsuro et al. (2017) The MUC5B promoter polymorphism is associated with specific interstitial lung abnormality subtypes. Eur Respir J 50:
Cahill, Katherine N; Katz, Howard R; Cui, Jing et al. (2017) KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. N Engl J Med 376:1911-1920
Wang, H-B; Akuthota, P; Kanaoka, Y et al. (2017) Airway eosinophil migration into lymph nodes in mice depends on leukotriene C4. Allergy 72:927-936

Showing the most recent 10 out of 39 publications